Moteur de recherche d’entreprises européennes
Financement de l’UE (5 988 155 €) : FABRICATION MULTI-MATÉRIAUX HYBRIDE À BASE D’ENCRE D’IMPLANTS DE NOUVELLE GÉNÉRATION Hor23/12/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
FABRICATION MULTI-MATÉRIAUX HYBRIDE À BASE D’ENCRE D’IMPLANTS DE NOUVELLE GÉNÉRATION
Improving the life quality of Europe’s increasingly elderly population is one of the most pressing challenges our society faces today. The need to treat age-related degenerative changes in e.g. articular joints or dental implants will boost the market opportunities for tissue regeneration products like biological scaffolds. State of the art 3D printing technologies can provide biocompatible implants with the right macroscopic shape to fit a patient-specific tissue defect. However, for a real functionality, there is a need for new biomaterials, technologies and processes that additionally allow the fabrication of a scaffold microstructure that induces tissue-specific regeneration. It is not possible to address the complexity in structure and properties of human tissues with a single material or fabrication technique. Besides, there are many types of tissue in the human body, each with their own internal structures and functions. INKplant vision is the fusion/combination of different biomaterials (6 different inks), high-resolution, high throughput additive manufacturing technologies already proved for industrial processes (ceramic sterolithography and 3D multimaterial inkjet printing), and advanced simulation and biological evaluation, to bring a new concept for the design and fabrication of biomimetic scaffolds (3D printed patient specific resorbable cell-free implants) which can address the complexity of the different tissue in the human body, demonstrated for 2 Use Cases. For a successful future translation, INKplant will consider all the relevant clinical adoption criteria already at the beginning of the development process. To address INKplant challenging objective the consortium includes the best expertise from the main areas of relevance to the project: biomaterials, 3D printing technology, tissue engineering, regulatory bodies and social humanities.
| 3D Matrix Europe SAS | 139 660 € |
| Asociacion Espanola de Normalizacion | 98 570 € |
| Biomed Center Innovation gGmbH | 414 660 € |
| Biotechnology Institute i Mas D | 270 080 € |
| Charite - Universitaetsmedizin Berlin | 383 506 € |
| Elkem Silicones France SAS | 273 644 € |
| Fluidinova SA | 140 219 € |
| Kepler Universitatsklinikum GmbH | 172 775 € |
| Lithoz GmbH | 406 200 € |
| Ludwig Boltzmann Gesellschaft Osterreichische Vereinigung ZUR Forderung DER Wissenschaftlichen Forschung | 303 934 € |
| Luxinergy GmbH | 161 000 € |
| Medizinische Universitaet Wien | 399 883 € |
| Profactor GmbH | 842 580 € |
| Stratasys Ltd. | 382 403 € |
| Tiger Coatings | 435 983 € |
| Transtissue Technologies GmbH | 340 529 € |
| Universidad Politecnica de Madrid | 216 125 € |
| Universitair Medisch Centrum Utrecht | 220 856 € |
| Universitat Linz | 385 550 € |
https://cordis.europa.eu/project/id/953134
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
